We have recently demonstrated that eEF1A2 is the main molecular target of plitidepsin, a marine drug currently in development for the treatment of multiple myeloma patients.9 Here we show that PKR is a novel eEF1A2-interacting partner, whose pro-apoptotic activity is regulated by the elongation factor likely through the inhibition of its kinase activity. Here, EEF1A2 is linked to plasma cell myeloma.